PATENT CLAIM ANALYSIS

Application Number: 16312847
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "252030"]

Abstract:
The invention concerns compounds that possess a high affinity at 5-HT 1A  receptors and an agonist efficacy, as measured by Emax values from a cellular activation assay, that is higher than that of the compounds described in prior art. The capacity of the compounds of the invention to activate an effector protein complex is higher than that the most efficacious agonist described in prior art. Compounds of the invention also exhibit an exceptionally high selectivity (Ki ratio greater than 1000-fold) with respect, in particular, to dopamine D2 receptors and adrenergic receptors of the alpha1 subtype. This selectivity which constitutes a great advantage since it means that the compounds will avoid inducing (central and peripheral) effects associated with activating or inhibiting such receptors.

Claim (Index 3):
A pharmaceutical composition comprising the compound according to  claim 1 .

Metadata:
- Claim Count in Document: 50.0
- Percentile: 98.0
- Lexical Diversity: 1.61446
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14971875', '15258320', '10415119', '10488842', '16046332']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7048662918295436
- 35 USC 102 Novelty (BERT): 0.5023826016953522
- Combined Prediction Score: 0.6846179228161245
- Mean Citation Score: 222.971462
- Max Citation Score: 228.85448
- Similarity Product: 162.89553128755568

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test